Bile acid buildup linked to aggressive breast cancer progression

Research from the University of Virginia (UVA) Comprehensive Cancer Center indicates that a buildup of bile acids, triggered by an unhealthy gut microbiome, can drive hormone receptor-positive (HR+) breast cancer to metastasize to other organs, particularly the lungs. According to Melanie Rutkowski, PhD, this mechanism suggests that FDA-approved bile acid sequestrants or microbiome replenishment could potentially prevent the spread of the disease.

How Gut Dysbiosis Fuels Breast Cancer Metastasis

The gut microbiome—the community of microorganisms in the intestines—acts as a regulator for bile acids. When this system falls into imbalance, a state known as “dysbiosis,” the body loses its ability to control these potent signaling molecules. According to Rutkowski, this failure creates a systemic environment that favors the spread of breast tumors.

The study, published in the journal Cancer Research, identifies a specific chain of events: gut dysbiosis leads to a buildup of bile acids, which then triggers harmful inflammation in the breast. This inflammation fuels the migration of cancer cells to distant sites. Audrey Putelo, PhD, a study co-author, noted that because bile acids can be measured and modified, this discovery provides a path toward identifying high-risk patients before metastasis occurs.

The Role of Bile Acid Sequestrants in Patient Survival

While the primary mechanisms were observed in lab mice, the UVA team analyzed data from human patients with HR+ breast cancer. They found a correlation between elevated bile acids, insulin resistance, and reduced survival rates.

Crucially, the researchers observed that patients with metastatic disease who were taking bile acid-suppressing medications—known as bile acid sequestrants—tended to live longer. These drugs are already FDA-approved for treating metabolic diseases. Rutkowski described the survival rates of these patients as “extremely encouraging,” especially since many patients on these medications have comorbid health issues that typically signal a worse prognosis.

Comparison: Current Treatment vs. Potential Preventative Approach

Future Directions in Microbiome-Based Oncology

The UVA findings point toward a shift in how clinicians might manage breast cancer risk. The research suggests two primary avenues for intervention: replenishing specific bacteria that modify bile acid composition or utilizing bile acid sequestrants to block the inflammatory triggers of metastasis.

This work is supported by the National Cancer Institute (grant 1R01CA253285) and the American Cancer Society. To speed the transition from lab to clinic, the UVA Comprehensive Cancer Center collaborates with the Paul and Diane Manning Institute of Biotechnology to accelerate the development of these treatments.

Frequently Asked Questions